The Savings Card Math Nobody Does
A $25 monthly price with an annual cap is not a $300 year. Working out the month your price changes.
Bottom line
- Eligible commercially insured patients may pay as little as $25/month for Foundayo with a savings card.
- Savings programs commonly carry annual caps on total assistance, at which point your cost reverts.
- Government insurance is typically excluded from manufacturer savings cards; Medicare Part D has its own separate route at $50/month for eligible patients from July 1, 2026.
- The number to establish is not the monthly price — it is the month the price changes.
Manufacturer savings cards are real and they save real money. They are also the most commonly misunderstood pricing instrument in prescription drugs, because the advertised monthly figure describes a rate rather than a duration.
How a savings card actually works
Your insurance adjudicates the claim and pays its share. You are left with an out-of-pocket amount. The savings card covers some or all of that amount, up to a limit. Three consequences follow, and none is obvious from the marketing:
- It requires coverage to exist. If your plan does not cover the drug for the indication, there is no adjudicated out-of-pocket amount for the card to reduce.
- Assistance is usually capped annually. The cap is measured in total dollars of assistance, not in months.
- Government insurance is typically excluded. Medicare, Medicaid, TRICARE and similar programs generally cannot be combined with manufacturer savings cards.
Take the annual assistance cap and divide it by the monthly assistance amount. That is the number of months you get the advertised price. Month N+1 is when your cost reverts — usually to whatever your plan's actual cost-sharing is, which can be a large step.
Worked illustration of cap mechanics
| If the cap is | And monthly assistance is | Months at the low rate | Price changes in |
|---|---|---|---|
| $1,800 | $150/mo | 12 | Month 13 — no mid-year change |
| $1,200 | $150/mo | 8 | Month 9 |
| $1,800 | $300/mo | 6 | Month 7 |
| $1,200 | $300/mo | 4 | Month 5 |
Illustrative arithmetic only. We are not publishing a specific cap figure for any product because caps and terms change and vary by program — get yours from the manufacturer's savings program terms in writing.
Applying this to Foundayo
The published figures are: as little as $25 per month for eligible patients with commercial insurance using a savings card; from $149 per month self-pay for the lowest dose; and $50 per month for eligible Medicare Part D patients beginning July 1, 2026.
Those are three separate routes, not tiers. The $25 route requires commercial insurance that covers the drug, plus an active savings card, plus remaining headroom under the annual cap. The Medicare route is separate precisely because government insurance is normally excluded from savings cards.
What is the annual assistance cap in dollars? What is my cost once the cap is reached? Does the cap reset on January 1 or on my enrollment anniversary? Does the assistance amount change if my dose increases? The fourth question catches most people — a higher dose can consume the cap faster.
The dose interaction
This is the part almost nobody models. If assistance covers a percentage or a fixed portion of a cost that rises with dose, then titrating upward consumes the annual cap faster. You can start the year expecting twelve months at the low rate and reach the cap in month eight because you moved to maintenance dose in month four.
The self-pay figure of $149 for the lowest dose carries the same structural caveat from the other direction: it is a lowest-dose price, and dose-tier pricing above it should be confirmed rather than assumed.
Compare against routes with no cap mechanics
All providers below are paid partners. Prices shown were recorded at publication and change without notice — always confirm on the provider's own page before you enrol.
Cash-pay marketplace for appointments with clinicians who prescribe FDA-approved brand-name medication only. No compounded product.
Check current pricing Paid partner linkCompounded oral tablets. Lowest verified oral semaglutide price among providers we list without a regulatory flag.
Check current pricing Paid partner linkSublingual semaglutide and oral tirzepatide, compounded.
Check current pricing Paid partner linkWhen the compounded comparison actually favours compounding
A flat compounded price has no cap and no eligibility cliff. Wellorithm's compounded oral semaglutide at $147 per month is $1,764 for a year with no month in which the price changes. If your savings card caps out in month eight and your cost reverts to a plan tier you have not checked, the flat price can win on annual total even though it loses on headline monthly rate.
That is a real argument for compounded product on price. It is also an argument that gets weaker every month, because the FDA proposed on April 30, 2026 to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, and a flat price you lose access to in month seven is not a flat price.
What to do
- Confirm your plan covers the drug for the indication, at what tier
- Get the savings program's annual cap and reset date in writing
- Calculate the month your price changes
- Ask what your cost becomes in that month
- Compare annual totals, not monthly rates
Sources & price verification
- AJMC, reporting on Foundayo savings card, self-pay, and Medicare Part D pricing.
- US Food and Drug Administration press announcement on approval of Foundayo, April 1, 2026.
- Provider pricing recorded from partner program data, September 2026.
- FDA proposed action on 503B Bulks List status, April 30, 2026.